| 30.9 1.13 (3.8%) | 10-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.45  |
1-year : | 45.47 |
| Resists | First : | 34.64 |
Second : | 38.93 |
| Pivot price | 30.56 |
|||
| Supports | First : | 27.7 | Second : | 23.04 |
| MAs | MA(5) : | 29.61 |
MA(20) : | 31 |
| MA(100) : | 33.71 |
MA(250) : | 29.49 |
|
| MACD | MACD : | -1.4 |
Signal : | -1.4 |
| %K %D | K(14,3) : | 38.2 |
D(3) : | 20.5 |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 43.25 | Low : | 21.02 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PHVS ] has closed below upper band by 41.3%. Bollinger Bands are 15% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 31.63 - 31.75 | 31.75 - 31.89 |
| Low: | 29.51 - 29.64 | 29.64 - 29.78 |
| Close: | 30.66 - 30.87 | 30.87 - 31.11 |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Fri, 16 Oct 2026
Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance Australia
Sat, 10 Oct 2026
Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance Singapore
Wed, 23 Sep 2026
A Pharvaris (PHVS) director proposes selling shares valued at $395,524. - Stock Titan
Wed, 23 Sep 2026
Trade Alert: Independent & Non-Executive Vice Chairman Of Pharvaris Hans J. G. C. Schikan Has Sold Stock - Simply Wall Street
Tue, 22 Sep 2026
Planned $7M Pharvaris (NASDAQ: PHVS) stock sale disclosed for founder shares - Stock Titan
Tue, 15 Sep 2026
PHVS Stock Rises 10% in a Month: What Is Driving the Rally? - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 70 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 6.1 (%) |
| Held by Institutions | 93.3 (%) |
| Shares Short | 2,010 (K) |
| Shares Short P.Month | 2,160 (K) |
| EPS | -3.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.9 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.4 % |
| Return on Equity (ttm) | -70.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -155 (M) |
| Levered Free Cash Flow | -90 (M) |
| PE Ratio | -10.1 |
| PEG Ratio | 0 |
| Price to Book value | 6.29 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|